JP2022543024A - ドラッグキャリアシステムとして用いられる、デキストランでコートされたシリカエアロゲル、及びデキストランでコートされたシリカエアロゲルの製造方法 - Google Patents
ドラッグキャリアシステムとして用いられる、デキストランでコートされたシリカエアロゲル、及びデキストランでコートされたシリカエアロゲルの製造方法 Download PDFInfo
- Publication number
- JP2022543024A JP2022543024A JP2022506345A JP2022506345A JP2022543024A JP 2022543024 A JP2022543024 A JP 2022543024A JP 2022506345 A JP2022506345 A JP 2022506345A JP 2022506345 A JP2022506345 A JP 2022506345A JP 2022543024 A JP2022543024 A JP 2022543024A
- Authority
- JP
- Japan
- Prior art keywords
- dextran
- silica airgel
- coated
- coated silica
- producing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 title claims abstract description 199
- 229920002307 Dextran Polymers 0.000 title claims abstract description 94
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 32
- 239000003937 drug carrier Substances 0.000 title claims abstract description 29
- 239000004965 Silica aerogel Substances 0.000 title abstract description 17
- 206010009944 Colon cancer Diseases 0.000 claims abstract description 22
- -1 dextran aldehyde Chemical class 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 15
- 125000003277 amino group Chemical group 0.000 claims abstract description 13
- 238000003980 solgel method Methods 0.000 claims abstract description 6
- 239000000377 silicon dioxide Substances 0.000 claims description 95
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 238000000576 coating method Methods 0.000 claims description 15
- 208000029742 colonic neoplasm Diseases 0.000 claims description 15
- 238000005406 washing Methods 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000011248 coating agent Substances 0.000 claims description 14
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 125000003172 aldehyde group Chemical group 0.000 claims description 8
- 239000011148 porous material Substances 0.000 claims description 7
- 239000004971 Cross linker Substances 0.000 claims description 5
- 239000002262 Schiff base Substances 0.000 claims description 5
- 150000004753 Schiff bases Chemical class 0.000 claims description 5
- 239000004115 Sodium Silicate Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 claims description 5
- 229910052911 sodium silicate Inorganic materials 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 3
- 230000032683 aging Effects 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 230000000717 retained effect Effects 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 description 49
- 239000003814 drug Substances 0.000 description 49
- 239000000243 solution Substances 0.000 description 22
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 15
- 229960002949 fluorouracil Drugs 0.000 description 15
- 210000002429 large intestine Anatomy 0.000 description 14
- 238000011068 loading method Methods 0.000 description 13
- 210000001072 colon Anatomy 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 11
- 102000004190 Enzymes Human genes 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- WYTZZXDRDKSJID-UHFFFAOYSA-N (3-aminopropyl)triethoxysilane Chemical compound CCO[Si](OCC)(OCC)CCCN WYTZZXDRDKSJID-UHFFFAOYSA-N 0.000 description 9
- 230000002496 gastric effect Effects 0.000 description 9
- 229910004298 SiO 2 Inorganic materials 0.000 description 8
- 230000008685 targeting Effects 0.000 description 8
- 239000002246 antineoplastic agent Substances 0.000 description 7
- 229920001661 Chitosan Polymers 0.000 description 6
- 108010001682 Dextranase Proteins 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000007605 air drying Methods 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 150000004676 glycans Chemical class 0.000 description 6
- 229920001282 polysaccharide Polymers 0.000 description 6
- 239000005017 polysaccharide Substances 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000002105 nanoparticle Substances 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- BOTDANWDWHJENH-UHFFFAOYSA-N Tetraethyl orthosilicate Chemical compound CCO[Si](OCC)(OCC)OCC BOTDANWDWHJENH-UHFFFAOYSA-N 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000000112 colonic effect Effects 0.000 description 4
- 229940127089 cytotoxic agent Drugs 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 230000000968 intestinal effect Effects 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000011275 oncology therapy Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 235000012239 silicon dioxide Nutrition 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000005095 gastrointestinal system Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940002612 prodrug Drugs 0.000 description 3
- 239000000651 prodrug Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 241000872931 Myoporum sandwicense Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000004964 aerogel Substances 0.000 description 2
- 238000006065 biodegradation reaction Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000003431 cross linking reagent Substances 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000017 hydrogel Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920005615 natural polymer Polymers 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- LFQCEHFDDXELDD-UHFFFAOYSA-N tetramethyl orthosilicate Chemical compound CO[Si](OC)(OC)OC LFQCEHFDDXELDD-UHFFFAOYSA-N 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 208000007416 Aberrant Crypt Foci Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000004804 Adenomatous Polyps Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229910020889 NaBH3 Inorganic materials 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 238000002444 silanisation Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000007723 transport mechanism Effects 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
- A61K9/122—Foams; Dry foams
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B33/00—Silicon; Compounds thereof
- C01B33/113—Silicon oxides; Hydrates thereof
- C01B33/12—Silica; Hydrates thereof, e.g. lepidoic silicic acid
- C01B33/14—Colloidal silica, e.g. dispersions, gels, sols
- C01B33/152—Preparation of hydrogels
- C01B33/154—Preparation of hydrogels by acidic treatment of aqueous silicate solutions
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B33/00—Silicon; Compounds thereof
- C01B33/113—Silicon oxides; Hydrates thereof
- C01B33/12—Silica; Hydrates thereof, e.g. lepidoic silicic acid
- C01B33/14—Colloidal silica, e.g. dispersions, gels, sols
- C01B33/157—After-treatment of gels
- C01B33/158—Purification; Drying; Dehydrating
- C01B33/1585—Dehydration into aerogels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
-ゾル・ゲル法によって合成されたシリカエアロゲルの表面改質
-改質されたシリカエアロゲル(S)の、デキストラン(D)又はデキストランアルデヒド(DA)でのコート
Claims (11)
- ドラッグキャリアシステムとして用いられる、デキストラン(D)でコートされたシリカエアロゲルの製造方法であって、
ゾル・ゲル法によって合成されるシリカエアロゲル(S)の表面を改質する工程と、
改質された前記シリカエアロゲル(S)をデキストラン(D)又はデキストランアルデヒド(DA)でコートする工程と、
を含むことを特徴とする方法。 - デキストラン(D)-シリカエアロゲル(S)結合用のグルタルアルデヒド(G)架橋剤を用いることによって、3-(アミノプロピル)トリエトキシシラン(A)で変成された前記シリカエアロゲル(S)の表面のアミン基と、グルタルアルデヒドのアルデヒド基との間でシッフ塩基反応を行い、グルタルアルデヒド(G)によってデキストラン(D)をシリカ表面にコートする、請求項1に記載の、デキストランでコートされたシリカエアロゲルの製造方法。
- 前記デキストランアルデヒド(DA)の構造のアルデヒド基と、APTES変成シリカエアロゲル表面のアミン基との間で安定なイミド結合を形成することによりデキストランアルデヒド(DA)-シリカエアロゲル(S)結合を形成することを特徴とする、請求項1に記載の、デキストランでコートされたシリカエアロゲルの製造方法。
- ケイ酸ナトリウムと水とを、好ましくは1:10の比で、常温で混合し、ゾルを形成してケイ酸ナトリウム由来のシリカエアロゲル(S)を得ることを特徴とする、請求項1~3のいずれか一項に記載の、デキストラン(D)でコートされたシリカエアロゲルの製造方法。
- 前記混合する工程の間、pH値が4になるように1MのHClを添加することによりゲル化pHを調整することを特徴とする、請求項4に記載の、デキストランでコートされたシリカエアロゲルの製造方法。
- 得られたゲルの網状構造を強化することを目的として、前記ゲルを空気乾燥機中、50℃で、好ましくは24時間、熟成させ、熟成工程後のゲル構造内の塩を除去するために水で洗浄することを特徴とする、請求項4又は5に記載のデキストランでコートされたシリカエアロゲルの製造方法。
- 洗浄後の空孔内の水を除去するために、エタノールで洗浄する工程を、好ましくは3回行い、エタノール中に入れられたゲルを、空気乾燥機中、50℃で、好ましくは24時間、保持することを特徴とする、請求項6に記載の、デキストランでコートされたシリカエアロゲルの製造方法。
- 前記ゲルの空孔内の前記エタノールを除去するためにn-ヘキサンで洗浄する操作を3回行い、前記ゲルを、n-ヘキサン中で、空気乾燥機中、50℃で保持し、24時間以内に3回n-ヘキサンで洗浄することを繰り返すことを特徴とする、請求項7に記載の、デキストランでコートされたシリカエアロゲルの製造方法。
- 前記合成されたシリカエアロゲル(S)を、入口温度を190℃に調整し、出口温度を80℃に調整した空気噴霧乾燥器内で乾燥させることを特徴とする、請求項8に記載の、デキストランでコートされたシリカエアロゲルの製造方法。
- 大腸癌の治療におけるドラッグキャリアシステムとして用いられる、デキストランでコートされたシリカエアロゲル。
- 大腸癌の治療におけるドラッグキャリアシステムとして用いられる、デキストランアルデヒドでコートされたシリカエアロゲル。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TR2019/11602 | 2019-07-31 | ||
TR201911602 | 2019-07-31 | ||
PCT/TR2020/050644 WO2021021049A1 (en) | 2019-07-31 | 2020-07-22 | A dextran coated silica aerogel used as a drug carrier system and a dextran coated silica aerogel production method |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022543024A true JP2022543024A (ja) | 2022-10-07 |
Family
ID=74228362
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022506345A Pending JP2022543024A (ja) | 2019-07-31 | 2020-07-22 | ドラッグキャリアシステムとして用いられる、デキストランでコートされたシリカエアロゲル、及びデキストランでコートされたシリカエアロゲルの製造方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20220267161A1 (ja) |
EP (1) | EP3999037A4 (ja) |
JP (1) | JP2022543024A (ja) |
WO (1) | WO2021021049A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102022124358A1 (de) * | 2022-09-22 | 2024-03-28 | Deutsches Zentrum für Luft- und Raumfahrt e.V. | Herstellung von hybriden Aerogelen |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH102875A (ja) * | 1996-04-19 | 1998-01-06 | Masao Karube | 酵素反応センサー及びその製造方法 |
JP2000502892A (ja) * | 1995-12-11 | 2000-03-14 | デンドレオン コーポレイション | 細胞分離の組成物、キット、および方法 |
JP2003526786A (ja) * | 2000-03-06 | 2003-09-09 | デイド・ベーリング・マルブルク・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | 多糖で被覆された担体、その製造および使用 |
WO2017104398A1 (ja) * | 2015-12-17 | 2017-06-22 | 株式会社日立ハイテクノロジーズ | 生体分子測定装置 |
-
2020
- 2020-07-22 EP EP20847813.1A patent/EP3999037A4/en active Pending
- 2020-07-22 JP JP2022506345A patent/JP2022543024A/ja active Pending
- 2020-07-22 WO PCT/TR2020/050644 patent/WO2021021049A1/en active Search and Examination
- 2020-07-22 US US17/631,540 patent/US20220267161A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000502892A (ja) * | 1995-12-11 | 2000-03-14 | デンドレオン コーポレイション | 細胞分離の組成物、キット、および方法 |
JPH102875A (ja) * | 1996-04-19 | 1998-01-06 | Masao Karube | 酵素反応センサー及びその製造方法 |
JP2003526786A (ja) * | 2000-03-06 | 2003-09-09 | デイド・ベーリング・マルブルク・ゲゼルシヤフト・ミツト・ベシユレンクテル・ハフツング | 多糖で被覆された担体、その製造および使用 |
WO2017104398A1 (ja) * | 2015-12-17 | 2017-06-22 | 株式会社日立ハイテクノロジーズ | 生体分子測定装置 |
Non-Patent Citations (4)
Title |
---|
""Development of dextran-coated silica aerogels as a drug release system for colon cancer treatment"", [ONLINE], vol. [検索日 2023.03.22], JPN6023013513, 2017, ISSN: 0005114651 * |
""The Use of L-Ascorbic Acid Containing Dextran Coated Silica Aerogel in Controlled Drug Targeting Sy", CONFERENCE: INTERNATIONAL IVEK BIO CONGRESS, vol. [online], JPN6023030176, 2018, pages 2023 - 07, ISSN: 0005114648 * |
INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 75, no. 3, JPN6023013507, 2013, pages 277 - 283, ISSN: 0005114650 * |
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, vol. 98, JPN6023013509, 2017, pages 691 - 700, ISSN: 0005114649 * |
Also Published As
Publication number | Publication date |
---|---|
WO2021021049A1 (en) | 2021-02-04 |
EP3999037A4 (en) | 2023-07-26 |
US20220267161A1 (en) | 2022-08-25 |
EP3999037A1 (en) | 2022-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tønnesen et al. | Alginate in drug delivery systems | |
Sun et al. | Preparation of pH-sensitive Fe3O4@ C/carboxymethyl cellulose/chitosan composite beads for diclofenac sodium delivery | |
Zhang et al. | Oral administration of chondroitin sulfate-functionalized nanoparticles for colonic macrophage-targeted drug delivery | |
Sinha et al. | Chitosan microspheres as a potential carrier for drugs | |
Kurakula et al. | Recent trends in design and evaluation of chitosan-based colon targeted drug delivery systems: Update 2020 | |
Lee et al. | Controlled drug release from pharmaceutical nanocarriers | |
Takka et al. | Evaluation of chitosan/alginate beads using experimental design: formulation and in vitro characterization | |
Das | Pectin based multi-particulate carriers for colon-specific delivery of therapeutic agents | |
Rani et al. | Chitosan based hydrogel polymeric beads–As drug delivery system | |
Du et al. | Layer-by-layer engineering fluorescent polyelectrolyte coated mesoporous silica nanoparticles as pH-sensitive nanocarriers for controlled release | |
Nanjwade et al. | Preparation and evaluation of carboplatin biodegradable polymeric nanoparticles | |
TWI439288B (zh) | 藥用載體及其製備方法與用途 | |
WO2023151350A1 (zh) | 交联玉米多孔淀粉负载姜黄素的复合凝胶微球及其制备方法 | |
Ergin et al. | A novel delivery system for enhancing bioavailability of S-adenosyl-l-methionine: Pectin nanoparticles-in-microparticles and their in vitro-in vivo evaluation' | |
Bajpai et al. | Investigation of dynamic release of vitamin B2 from calcium alginate/chitosan multilayered beads: Part II | |
CN111603436A (zh) | 一种光动力二氧化硅纳米材料@水凝胶复合载药系统、其制备方法及其应用 | |
Ibrahim | Advances in polysaccharide-based oral colon-targeted delivery systems: the journey so far and the road ahead | |
Kim et al. | Preparation of nanosize alginate gel using pluronic-based nano-carrier as a template | |
JP2022543024A (ja) | ドラッグキャリアシステムとして用いられる、デキストランでコートされたシリカエアロゲル、及びデキストランでコートされたシリカエアロゲルの製造方法 | |
Deshmukh | Bridging the gap of drug delivery in colon cancer: The role of chitosan and pectin based nanocarriers system | |
Karewicz et al. | New bilayer-coated microbead system for controlled release of 5-aminosalicylic acid | |
CN101953797B (zh) | 一种载药缓控释纳米材料的制备方法和应用 | |
Deep et al. | Prospective of natural gum nanoparticulate against cardiovascular disorders | |
JP5715139B2 (ja) | 消化管に存在する望ましくない分子を特異的に吸着し得る医学製剤 | |
Singh et al. | Polysaccharide-based nanoparticles: nanocarriers for sustained delivery of drugs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220325 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230404 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230615 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230725 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240305 |